IRVINE, Calif., December 6, 2022–(BUSINESS WIRE)–Genomic Testing Cooperative, LCA (GTC) announced the presentation of four innovative studies at the American Society of Hematology (ASH) annual meeting, being held December 10-13, 2022 in New Orleans, Louisiana, will take place . The studies underscore and validate the value of the advanced molecular profiling tests currently offered by GTC in the evaluation of hematological neoplasms using next-generation DNA and RNA sequencing (NGS).
GTC reports that by combining targeted transcriptome with a proprietary machine learning algorithm, they can predict which patients with advanced myelodysplastic syndrome/acute myeloid leukemia will respond to treatment with venetoclax-based therapy. In another study, GTC shows that combining targeted transcriptome with machine learning can predict which patients will develop acute graft-versus-host disease (aGVHD), not only post-transplant, but also from a pre-transplant sample , suggesting that the patient’s own bone bone marrow microenvironment may contribute to the development of aGVHD.
GTC continues to demonstrate the superior capabilities of its new cell-free (cfDNA) and cell-free RNA (cfRNA) liquid biopsy test called Liquid Trace™. Using cfRNA, GTC studies indicate that cfRNA levels can be used in “liquid immunoprofiling” of hematological neoplasms. The combination of this liquid immunophenotyping with machine learning algorithms shows high reliability in differential diagnosis between different types of lymphoid neoplasms/lymphomas.
A fourth study examined the differences in somatic mutations and outcomes in primary central nervous system lymphoma between Hispanic and non-Hispanic patients.
“The work presented at ASH reflects GTC’s commitment to be the diagnostics leader in innovation and advancement in the science of biomarker diagnostics and discovery, particularly in hematological neoplasms,” said Dr. Maher Albitar, Founder, Chief Executive Officer and Chief Medical Officer of GTC. “The use of RNA profiling in tissue and liquid biopsies opens up new horizons in diagnostics, especially in combination with artificial intelligence. Because of the collaborative business model that GTC has adapted as a cooperative (Co-Op) company, we are able to be leaders. The commitment of all members of the cooperative to work closely with GTC to improve patient care and advance precision medicine has made this work possible.” added Dr Albitar.
Below is a list of GTC presentations:
1) DNA and RNA profiles in the machine learning algorithm to predict which patients with AML/MDS will respond to venetoclax-based therapy. Sunday, December 11, 2022: 6:00 p.m. – 8:00 p.m
2) Liquid immunophenotyping and the diagnosis of lymphoid neoplasms using cell-free RNA. Sunday, December 11, 2022: 6:00 p.m. – 8:00 p.m
3) Using targeted transcriptome and machine learning of bone marrow samples before and after transplantation to predict acute GVHD (aGVHD) and overall survival after allogeneic HSC transplantation. Saturday, December 10, 2022: 5:30 p.m. – 7:30 p.m
4) Differences in somatic mutations and outcomes in primary central nervous system lymphoma comparing Hispanic and non-Hispanic patients. Saturday, December 10, 2022: 5:30 p.m. – 7:30 p.m
Please visit GTC booth #205 in ASH exhibition hall for more information.
About Genomic Testing Cooperative, LCA
Genomic Testing Cooperative (GTC) is a privately held molecular testing company based in Irvine, California. The company operates on a cooperative (co-op) business model. The members of the cooperative hold type A shares with voting rights. The Company offers its patron members a full suite of comprehensive genomic profiling, primarily based on next-generation sequencing. Molecular changes are identified through rigorous testing using specially designed algorithms to increase accuracy and efficiency. The clinical relevance of the detected changes is drawn from numerous databases using internally developed software. The relevance of the results for diagnosis, prognosis, therapy selection and prognosis of the result is communicated to the members. The co-op model allows GTC to make the testing and information platform available to members at a lower cost due to less overhead. For more information, visit https://genomictestingcooperative.com/.
Forward-Looking Statements
All statements, expectations and assumptions contained in this press release are forward-looking statements. Such forward-looking statements are based on GTC management’s current expectations and include statements about the value of comprehensive genomic profiling, RNA profiling, DNA profiling, algorithms, therapy and the ability of tests to provide clinically useful information. All information in this press release is as of the date of publication and GTC assumes no obligation to update this information except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221206005168/en/
contacts
Jennifer Varca
Genome testing cooperative.
(949) 540-9421
[email protected]
